<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>14</Volume>
				<Issue>7</Issue>
				<PubDate PubStatus="epublish">
					<Year>2013</Year>
					<Month>07</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Efficacy and Safety of Endostar® Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>4255</FirstPage>
			<LastPage>4259</LastPage>
			<ELocationID EIdType="pii">27940</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;b&gt;Background:&lt;/b&gt; Soft tissue sarcomas (STS) are a heterogeneous group of tumors, and approximately 40-50%of patients with STS develop metastatic disease. The median overall survival of those patients was 12 monthsand their 5-year survival rate was 8%. Therefore, study on more effective treatment, especially the targetingtherapies, is urgently needed. &lt;br/&gt;&lt;b&gt;Objective&lt;/b&gt;: To evaluate the efficacy and safety of Endostar® combined withchemotherapy in patients with advanced STS. &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: A retrospective case-series study was conducted inCancer Institute of PLA, Xinqiao Hospital. A total of 71 patients suffering from advanced STS (IIB - IV) wereincluded, of whom 49 cases treated with chemotherapy alone were defined as the control group and the rest 22cases treated with the traditional chemotherapy combined with Endostar® were defined as the test group. Theshort-term therapeutic effects including objective response rate (ORR), disease control rate (DCR) and safetywere evaluated in the two groups. In the follow-up, progression-free survival (PFS) and overall survival (OS)were also observed. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: In the test and control groups, the ORR was 18.2% and 12.2%, respectively (P =0.767), and the DCR was 86.4% and 61.2%, respectively (P=0.034). The median time to progression in the testand control groups was 120 days and 70 days with significant difference (P = 0.017), while the median overallsurvival was 452 days and 286 days without significant difference (P = 0.503). The one-year survival rate in thetest group and control group was 56.2% and 35.4%, respectively, while the two-year survival rate was 30.2% and26.5%, respectively. No significant difference in the side effects was found between the two groups. &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;:Endostar® combined with chemotherapy resulted in a higher DCR and longer PFS in the patients with advancedSTS, and the toxicity was tolerable.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Soft tissue sarcomas (STS)</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Endostatin</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">antiangiogenic</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Survival Analysis</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_27940_2cad701506ea2e33c40733b617f3e620.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
